MYOPIC PRESENTATION OF CENTRAL SEROUS CHORIORETINOPATHY.
Journal
Retina (Philadelphia, Pa.)
ISSN: 1539-2864
Titre abrégé: Retina
Pays: United States
ID NLM: 8309919
Informations de publication
Date de publication:
01 Dec 2021
01 Dec 2021
Historique:
pubmed:
7
9
2021
medline:
15
1
2022
entrez:
6
9
2021
Statut:
ppublish
Résumé
To increase insight into the myopic presentation of central serous chorioretinopathy (CSC) by comparing a large group of myopic patients with CSC with reference groups with only one of the diagnoses. Myopic patients with CSC (spherical equivalent ≤-3D, n = 46), emmetropic patients with CSC (spherical equivalent -0.5 to 0.5 D, n = 83), and myopic, non-CSC patients (n = 50) were included in this multicenter cross-sectional study. Disease characteristics and imaging parameters, such as subfoveal choroidal thickness and indocyanine green angiography patterns, were compared between cases and reference groups. In myopic patients with CSC, median subfoveal choroidal thickness (286 µm [IQR 226-372 µm]) was significantly thicker than subfoveal choroidal thickness in myopic, non-CSC patients (200 µm [IQR 152-228 µm], P < 0.001) but thinner than emmetropic patients with CSC (452 µm [IQR 342-538 µm], P < 0.001). They also had pachyvessels in 70% of the eyes comparable with emmetropic CSC (76%, P = 0.70). Choroidal hyperpermeability was frequently present on indocyanine green angiography in both myopic and emmetropic CSC eyes. Need for treatment, treatment success, and recurrence rate were not significantly different between CSC groups. Myopic CSC presents with similar imaging and clinical characteristics as emmetropic CSC, apart from their thinner choroids. Keeping in mind the structural changes of myopia, other imaging characteristics could aid the diagnostic process.
Identifiants
pubmed: 34483315
doi: 10.1097/IAE.0000000000003297
pii: 00006982-202112000-00007
doi:
Substances chimiques
Coloring Agents
0
Indocyanine Green
IX6J1063HV
Types de publication
Comparative Study
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
2472-2478Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Opthalmic Communications Society, Inc.
Références
Gass JD. Pathogenesis of disciform detachment of the neuroepithelium. Am J Ophthalmol 1967;63:1–139.
Spaide RF, Hall L, Haas A, et al. Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996;16:203–213.
Yannuzzi LA, Shakin JL, Fisher YL, Altomonte MA. Peripheral retinal detachments and retinal pigment epithelial atrophic tracts secondary to central serous pigment epitheliopathy. Ophthalmology 1984;91:1554–1572.
Kim YT, Kang SW, Bai KH. Choroidal thickness in both eyes of patients with unilaterally active central serous chorioretinopathy. Eye (Lond) 2011;25:1635–1640.
Chung YR, Kim JW, Choi SY, et al. Subfoveal choroidal thickness and vascular diameter in active and resolved central serous chorioretinopathy. Retina 2018;38:102–107.
Chen G, Tzekov R, Li W, et al. Subfoveal choroidal thickness in central serous chorioretinopathy: a meta-analysis. PLoS One 2017;12:e0169152.
Kang NH, Kim YT. Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy. Eye (Lond) 2013;27:387–391.
Kim DY, Joe SG, Yang HS, et al. Subfovael choroidal thickness changes in treated idiopathic central serous chorioretinopathy and their association with recurrence. Retina 2015;35:1867–1874.
Wei WB, Xu L, Jonas JB, et al. Subfoveal choroidal thickness: the Beijing eye study. Ophthalmology 2013;120:175–180.
Ersoz MG, Arf S, Hocaoglu M, et al. Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients. Br J Ophthalmol 2019;103:725–729.
Yzer S, Fung AT, Barbazetto I, et al. Central serous chorioretinopathy in myopic patients. Arch Ophthalmol 2012;130:1339–1340.
van Dijk EHC, de Roon Hertoge KL, Boon CJF. Central serous chorioretinopathy in a myopic patient with pachychoroid. Ophthalmol Point Care 2017;1:e26–e29.
Peponis VG, Chalkiadakis SE, Nikas SD, et al. Bilateral central serous retinopathy following laser in situ keratomileusis for myopia. J Cataract Refract Surg 2011;37:778–780.
Ikram MA, Brusselle GGO, Murad SD, et al. The Rotterdam study: 2018 update on objectives, design and main results. Eur J Epidemiol 2017;32:807–850.
Maruko I, Iida T, Sugano Y, et al. One-year choroidal thickness results after photodynamic therapy for central serous chorioretinopathy. Retina 2011;31:1921–1927.
van Rijssen TJ, van Dijk EHC, Yzer S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res 2019;73:100770.
Staurenghi G, Sadda S, Chakravarthy U, Spaide RF. Proposed lexicon for anatomic landmarks in normal posterior segment spectral-domain optical coherence tomography: the IN•OCT consensus. Ophthalmology 2014;121:1572–1578.
Spaide RF, Ryan EH. Loculation of fluid in the posterior choroid in eyes with central serous chorioretinopathy. Am J Ophthalmol 2015;160:1211–1216.
Cheung CMG, Lee WK, Koizumi H, et al. Pachychoroid disease. Eye (Lond) 2019;33:14–33.
Spaide RFM, Ledesma-Gil GMD, Gemmy Cheung CMM. Intervortex venous anastomosis in pachychoroid-related Disorders. Retina 2020. Available at: https://journals.lww.com/retinajournal/Abstract/9000/Intervortex_Venous_Anastomosis_in.95698.aspx . Accessed March 8, 2021.
Manayath GJ, Arora S, Parikh H, et al. Is myopia a protective factor against central serous chorioretinopathy? Int J Ophthalmol 2016;9:266–270.
Flores-Moreno I, Lugo F, Duker JS, Ruiz-Moreno JM. The relationship between axial length and choroidal thickness in eyes with high myopia. Am J Ophthalmol 2013;155:314–319.e1.
Yang L, Jonas JB, Wei W. Choroidal vessel diameter in central serous chorioretinopathy. Acta Ophthalmol 2013;91:e358–e362.
Castro-Correia J, Coutinho MF, Rosas V, Maia J. Long-term follow-up of central serous retinopathy in 150 patients. Doc Ophthalmol 1992;81:379–386.
Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology 1996;103:2070–2080.
van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology 2018;125:1547–1555.
Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 2013;41:201–214.
Loo RH, Scott IU, Flynn HW, et al. Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. Retina 2002;22:19–24.
Shiragami C, Takasago Y, Osaka R, et al. Clinical features of central serous chorioretinopathy with type 1 choroidal neovascularization. Am J Ophthalmol 2018;193:80–86.
Wong TY, Ferreira A, Hughes R, et al. Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol 2014;157:9–25.e12.